{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
INN:fipravirimat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03725852: Phase 2 Interventional Completed Idiopathic Pulmonary Fibrosis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04504526: Early Phase 1 Interventional Unknown status Lymphoma
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01916135: Phase 1 Interventional Completed Carcinoma
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:geclosporin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Geclosporin (Cyclosporine) is an immunosuppressive agent, that is used to prevent rejection of a transplanted organ by the body. Geclosporin is isolated from a fungus, Beauveria nivea, and was first discovered in 1970. By suppressing the immune system, this drug prevents white blood cells from rejecting the transplanted organ. Geclosporin primarily does this by suppressing T cells and T cell cytokine production, but also acts in other ways, for example by inhibiting growth and activation of B cells and antigen presenting cells, and by reducing antibody production. Geclosporin is usually combined with other compounds, and has been studied as potential treatment for a large range of disorders. It is used for the treatment of several other conditions, such as severe recalcitrant plaque psoriasis, severe active rheumatoid artritis, and to prevent rejection of donor cells as a result of bone marrow transplantation. Relapse after discontinuation of this compound is to be expected, and therefore, patients should receive maintenance therapy at the lowest effective dosage. The most common adverse events are hypertrichosis, gingival hyperplasia, and neurological and gastrointestinal effects. Renal dysfunction is also possible, but irreversible damage is rare.
Status:
Investigational
Source:
NCT02423577: Phase 2 Interventional Completed Influenza
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04262856: Phase 2 Interventional Active, not recruiting Non Small Cell Lung Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02897869: Phase 1 Interventional Completed Healthy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Murepavadin is the first in class of the outer membrane protein-targeting antibiotics (OMPTA) and a pathogen-specific peptidomimetic antibacterial with a novel, nonlytic mechanism of action targeting Pseudomonas aeruginosa. Murepavadin is being developed by Polyphor Ltd for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia. In preclinical studies, Murepavadin was highly effective against Pseudomonas aeruginosa, without evidence of generating resistance. Murepavadin has been evaluated in 8 clinical studies. Murepavadin penetrates into lung tissue and showed encouraging results in a Phase II study when given on top of standard of care in patients with Ventilator-Associated Bacterial Pneumonia. The phase III clinical trial was initiated in 2018 to assess the efficacy, safety, and tolerability of Murepavadin in adult subjects with ventilator-associated bacterial pneumonia. But in May 2019, Polyphor Ltd. suspended the global phase III trial for safety data review.
Status:
Investigational
Source:
INN:linvencorvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03823989: Phase 1 Interventional Completed Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
